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Glycolipid mimetics consisting of a bicyclic polyhydroxypiperidine-cyclic carbamate core and a pseu-
doanomeric hydrophobic tail, termed sp2-iminosugar glycolipids (sp2-IGLs), target microglia during
neuroinﬂammatory processes. Here we have synthesized and investigated new variants of sp2-IGLs for
their ability to suppress the activation of human monocyte-derived dendritic cells (DCs) by lipopoly-
saccharide (LPS) signaling through Toll-like receptor 4. We report that the best lead was (1R)-1-
dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin (DSO2-ONJ), able to inhibit LPS-induced TNFa pro-
duction and maturation of DCs. Immunovisualization experiments, using a mannoside glycolipid con-
jugate (MGC) that also suppress LPS-mediated DC activation as control, evidenced a distinct mode of
action for the sp2-IGLs: unlike MGCs, DSO2-ONJ did not elicit internalization of the LPS co-receptor CD14
or induce its co-localization with the Toll-like receptor 4. In a mouse model of LPS-induced acute
inﬂammation, DSO2-ONJ demonstrated anti-inﬂammatory activity by inhibiting the production of the
pro-inﬂammatory interleukin-6. The ensemble of the data highlights sp2-IGLs as a promising new class of
molecules against inﬂammation by interfering in Toll-like receptor intracellular signaling.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
sp2-Iminosugars are an original family of sugar look-alikes
possessing a pseudoamide-type nitrogen atom with a high sp2-
hybridation character at the position of the endocyclic oxygen
[1e3], with the unique property of mimicking not only the struc-
ture and function of the natural counterparts, as classical imino-
sugars do, but also their chemistry [4]. Most signiﬁcantly, sp2-
iminosugars can engage in glycosylation reactions, affording stable
glycoconjugate analogs capable of agonizing or antagonizing the
biological processes inwhich the natural counterparts are involved.
Examples that illustrate the opportunities that sp2-iminosugar(C.G. Mueller), mellet@us.es
served.conjugates offer in biology and medicine are the design of phar-
macological chaperones targeting lysosomal glycosidases [5], the
synthesis of multivalent constructs to explore multivalent enzyme
inhibition [6] or the preparation of Tn antigen glycopeptide mimics
[7].
Pursuing our interest in the potential of sp2-iminosugars as
monosaccharide surrogates for neoglycoconjugate drug develop-
ment, we recently turned our attention to glycolipids as immu-
noactive agents for clinical and mechanistic applications, a very
active research area in medicinal chemistry. Studies report that
glycolipids exert antiinﬂammatory and antiproliferative activity, as
well as beneﬁcial effects on lipid metabolism [8]. The chemical
synthesis of glycolipid analogs is often challenging, however,
especially when it comes to producing pure anomeric forms of the
sugar head group. Remarkably, sp2-iminosugars beneﬁt from an
exacerbated anomeric effect, which warrants total a-stereo-
selectivity during O-, S or N- glycosylation steps and imparts
Fig. 1. Structures of sp2-IGL derivatives (1e8) and the mannoside glycolipid conjugate
(MGC) 9 evaluated in this study.
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Indeed, some sp2-iminosugar glycolipids (sp2-IGLs) have been
already prepared and found to exhibit a range of bioactivities
including anti-proliferative [9], anti-metastatic [10,11], anti-
parasitic [12] and anti-neuroinﬂammatory activity [13,14]. The
sp2-IGL representatives (1R,SR)1-dodecylsulﬁnyl-5N,6O-oxome-
thylidenenojirimycin (R-DSO-ONJ) and (1R)-1-dodecylsulfonyl-
5N,6O-oxomethylidenenojirimycin (DSO2-ONJ) were particularly
efﬁcient at inhibiting the lipopolysaccharide (LPS)-induced in-
ﬂammatory signaling in mouse Bv.2 microglial cells by decreasing
inducible nitric oxide synthase (iNOS) and pro-inﬂammatory
cytokine production and simultaneously upregulating production
of the anti-inﬂammatory cytokine IL-10. The latter compound was
able to signiﬁcantly reduce reactive gliosis in retinal explants of the
diabetic db/db mice model that recapitulates the progression of
diabetic retinopathy [14,15]. Although initially the protein target
was hypothesized to be an endoplasmic reticulum a-glucosidase,
the sp2-IGLs were found not to impact glycoprotein biosynthesis,
which is consistent with their lack of toxicity in healthy cells [16].
Instead, they seemed to interfere with the mitogen activated pro-
tein kinase (MAPK) cascade, at the crossroad between immunity
and cancer, offering new therapeutic opportunities.
Dendritic cells (DCs), present in most tissues and body liquids,
are key players in the initiation and polarization of the immune
response [17]. The investigation of key indicators of the inﬂam-
matory response in DCs upon treatment with sp2-IGLs was there-
fore mandatory to validate the above notion. These immune
sentinels are highly sensitive to innate immune stimuli and mature
into professional antigen-presenting cells producing inﬂammatory
cytokines, such as TNFa, and upregulating the T cell co-stimulators
CD83 and CD86 at the cell surface. Mature DCs are highly efﬁcient
in priming the T cell-mediated adaptive immune response [17]. A
particularly efﬁcient DC stimulator is LPS, an important toxin found
in the outer membrane of Gram-negative bacteria involved in the
development of septic shock, characterized by the hyperproduction
of inﬂammatory cytokines and organ damage [18]. LPS-elicited
acute inﬂammatory responses are mediated by the signaling re-
ceptor Toll-like receptor (TLR)-4. The signaling cascade is activated
by the successive interaction of LPS with the lipopolysaccharide
binding protein, the cluster differentiation antigen CD14, and the
myeloid differentiation protein (MD-2) that binds LPS and presents
it in amonomeric form toTLR-4 [19]. TLR-4 undergoes dimerization
and recruits downstream adaptor proteins, which initiates an
intracellular signaling cascade that leads to nuclear translocation of
transcription factors and the biosynthesis of pro-inﬂammatory
cytokines and interferons [20,21]. Therefore, therapeutic in-
terventions to reduce TLR-4 signaling in response to LPS are of
clinical importance.
With the objective to gather information on the mode of action
of sp2-IGLs and on the structural features that determine their anti-
inﬂammatory properties, we have now generated a series of de-
rivatives 1e8 (Fig. 1) that keep the dodecylsulﬁnyl or dode-
cylsulfonyl lipidic aglycone moiety but differ in the hydroxylation
pattern (D-gluco, D-galacto or D-manno) of the sp2-iminosugar
aglycone, and studied their capacity to inhibit the activation of
human DCs by LPS. The sulfone derivative DSO2-ONJ (compound 3),
having a hydroxylation proﬁle of structural complementarity to a-
D-glucopyranosides, emerged as the most active member in
reducing TNFa production and downregulating the DC maturation
markers CD83 and CD86. Interestingly, co-localization studies
support that sp2-IGLs act by inhibition of intracellular signaling
rather than bymodifying LPS receptor cell-surface localization. This
behavior is sharply different from that reported for other neo-
glycolipids such as the mannoside glycolipid conjugate (MGC) 9
(Fig. 1), which suppress TLR-4 signaling in human DCs by targetingearly membrane steps of the CD14dTLR-4 signaling membrane
complex [22e24]. In a mouse model of endotoxin shock, sp2-IGL 3
reduced the production of the inﬂammatory interleukin 6 (IL-6),
supporting its therapeutic potential.2. Results
2.1. Design rational and synthesis
Compounds 1e8 were chosen for the initial cell toxicity and
anti-inﬂammatory activity-screening, primarily because sp2-IGLs
bearing sulfur anomeric functional groups and twelve-carbon
aliphatic aglycones were previously identiﬁed as privileged struc-
tures in anti-cancer/anti-inﬂammatory tests in different settings
[13,14,16]. The sulﬁnyl and sulfonyl derivatives, differing in their
oxidation state, have been suggested [14] to emulate the phosphate
group in anti-inﬂammatory phosphatidylinositol analogs (PIAs)
and alkyl ether lipids (e.g., perifosine) for which a mechanism of
action involving p38 MAPK binding has been evidenced [25].
Dodecyl-sulﬁnyl and -sulfonyl conjugates were therefore consid-
ered with sp2-iminosugar moieties that mimic D-gluco (1e3), D-
Scheme 2. Synthesis of the D-manno-conﬁgured sp2-IGLs 7 and 8.
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the effect of the glycone conﬁguration in the anti-inﬂammatory
activity.
Compounds 1e3 were prepared following previously reported
procedures [12,14]. The chemical syntheses of the new derivatives
4e8 follow a general scheme involving (i) steroselective a-S-gly-
cosidation of the corresponding peracetylated sp2-iminosugar (10
or 14) with dodecanethiol and (ii) partial or full oxidation of the
thioglycoside intermediate (11 or 15) with m-chloroperbezoic acid
(m-CPBA) to afford the target sulfoxide and sulfone sp2-IGLs,
respectively (Schemes 1 and 2). In the case of the galacto-conﬁg-
ured sulfoxides, both the (SS) and the (RS) diastereomers 12 and 13
were formed in close to 1:1 ratio and could be separated by column
chromatography before deacetylation to give 4 and 5, respectively.
Their absolute stereochemistry was assigned based on their 1H
NMR spectra. Notably, the H-5 resonance was deshielded by
0.67 ppm in 12 (d 4.96 ppm) compared with 13 (d 4.29 ppm).
Literature data on alkyl a-D-glycosyl sulfoxides support then the
(SS) assignment for the ﬁrst one, where H-5 and the sulfoxide ox-
ygen would be located in close proximity in the more favourable
exoanomeric-type conformation, that is, with C-2 in the ring and
the exocyclic methylene carbon in anti-disposition [26]. The lower
magnetic nonequivalence (Dd) of the methylene protons vicinal to
the chiral sulfur atom (SOCH2) for 12 (57 Hz) as compared with 5
(81 Hz) is also in agreement with the NMR properties reported in
the literature for (SS) and the (RS) alkyl a-D-glycosyl sulfoxides,
respectively [27]. The partial oxidation of the manno-conﬁgured
thioglycoside 15 afforded a major sulfoxide product (16) that was
obtained in pure form after column chromatography and assigned
the (SS) conﬁguration based on the Dd value for the SOCH2 protons
(48 Hz) [27]. The (RS) diastereomer was detected in the reaction
mixture as a trace compound but could not be isolated in pure form.
Finally, deacetylation of 16 by treatment with sodium methylate
afforded the fully unprotected target sp2-IGL 7.2.2. Toxicity of sp2-IGLs on DCs
Human monocyte-derived dendritic cells (DCs) were differen-
tiated from monocytes puriﬁed from the blood of different donors.
The cytotoxicity of the sp2-IGL derivatives was evaluated by incu-
bation of the individual components 1e8 at 25 and 50 mM con-
centrations for 24 h, followed by exposure to 7-aminoactinomycin
D, a DNA-intercalating ﬂuorescent dye that only penetrates the cell
upon cell death. As control, DMSO solvent was added. Assays were
performed in parallel in the absence and presence of 100 ngmL1
LPS. In its absence, the mean cell viability did not fall below an 80%Scheme 1. Synthesis of the D-galacto-conﬁgured sp2-IGLs 4e6.threshold at 25 mMor a 70% limit at 50 mMupon treatment with the
sp2-IGLs (Fig. 2a and b). However, in the presence of LPS, cell
viability was reduced and fell below 70% for compounds 5 and 6 at
50 mM (Fig. 2a and b). DMSO had no signiﬁcant impact on cell
viability irrespective of LPS. To be in a relatively safe window, we
settled the dose limit to 50 mM for future experimentation with the
sp2-IGLs.2.3. sp2-IGLs inhibit LPS activation of human DCs
We next examined the capacity of the selected sp2-IGLs repre-
sentatives to inhibit the activation of DCs by LPS. By stimulating
TLR-4-signaling, LPS is a potent activator of DCs leading to the
production of TNFa and the upregulation of the T cell co-
stimulators CD83 and CD86. A 24 h exposure time to LPS in the
absence or presence of 25 mM and 50 mM of sp2-IGLs was estab-
lished to warrant signiﬁcant expression of endogenous CD83 and
CD86 [28,29]. LPS induced the production of TNFa, as determined
by ELISA, but there was a signiﬁcant reduction of TNFa by com-
pound 3 at 25 mM and by compounds 3e8 at 50 mM (Fig. 3a and b).
The expression of CD83 and CD86 on the cell surface was subse-
quently assessed by ﬂuorescence-activated ﬂow cytometry (FACS).
At 25 mM, compounds 1 and 4 signiﬁcantly reduced CD83 levels
(Fig. 3c). As for CD86, only compound 3 was active at both 25 mM
and 50 mM (Fig. 3d). These results showed that most sp2-IGLs
inhibited to some extent LPS-mediated DC maturation, compound
3 being the most active. Subsequent analysis of its TNFa production
dose-dependent inhibition on LPS-activated DCs (Fig. 4a) allowed
us to establish the dose-response curve for compound 3 and its IC50
at 20± 10 mM (Fig. 4b). Its efﬁcient downregulatory effect of CD86
expression was also conﬁrmed (Fig. 4c), while there was a signiﬁ-
cant reduction of CD83 expression only at 50 mM (Fig. 4d). Taken
together, the sp2-IGL 3 displayed a signiﬁcant anti-LPS activity us-
ing human DCs as test cells.2.4. sp2-IGL 3 remains active post-LPS exposure
We previously showed that the mannoside glycolipid (MGC) 9
counteracted LPS activation of DCs at similar concentrations as
those now encountered for the sp2-IGL 3 [22]. In order to explore
whether or not the two glycolipid mimics behave through similar
mechanisms, a direct comparison of compound 3 with MGC 9 for
their capacity to antagonize LPS in its stimulatory activity on DCs
was conducted. It was observed that MGC 9 impaired TNFa
Fig. 2. Effect of sp2-IGLs on the viability of human DCs. The different sp2-IGL compounds were used at (a) 25 mM and (b) 50 mM. Solvent controls were performed with DMSO at 0.5
and 1%. Cell viability in the absence or presence of LPS (100 ngmL1) was measured after 24 h by 7-aminoactinomycin D (7-AAD) staining, followed by ﬂow cytometry analysis. Each
point corresponds to a different monocyte blood donor.
Fig. 3. sp2-IGLs are anti-inﬂammatory for LPS-activated DCs. Cells were stimulated with LPS (100 ngmL1) in the absence or presence of sp2-IGLs for 24 h (a, 25 mM; b, 50 mM) Effect
on the pro-inﬂammatory cytokine TNF-a released in the media. (c, d) Effect on the relative expression of CD83 and CD86 cell surface maturation markers. Non-treated cells (n.t.;
control) or treated with the solvent (DMSO) are indicated. Data correspond to at least 3 cell donors/independent assays. Bars represent means ± SEM.
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same time as LPS or 0.5 h after LPS exposure (Fig. 5a and b).
During the ﬁrst hour of LPS stimulation of macrophages there is
an initial delay in the production of biologically active TNFa [30].
This is followed by a rapid increase in TNFa accumulation, reaching
a peak by 3 h, followed by a rapid decline, and reaching a plateau in
TNFa accumulation in the supernatant by 6 h [31]. Thus, it was of
interest to examine sp2-IGL 3 versus MGC 9 regulation of TNFa
production during this time frame. When the compounds were
added 2 h, 4 h or 6 h after LPS, it was apparent that while inhibitionby compound 3 remained essentially constant, there was a clear
loss of MGC 9 activity (Fig. 5a and b). Analysis of CD83 and CD86
markers conﬁrmed these properties (SI, Fig. S1). In summation,
MGC 9 was found to be a more potent anti-inﬂammatory agent
when added conjointly with LPS, but compound 3 displayed amore
efﬁcient post-LPS inhibitory activity.
2.5. The mode of operation of sp2-IGLs and MGC 9 are different
The above ﬁndings suggest that the mode of action differs
Fig. 4. Anti-inﬂammatory effects of sp2-IGL 3 in DCs. Cells were stimulated with LPS (100 ngmL1) in the absence or presence of 3, as in Fig. 3. After 24 h, analyses were performed
for (a) TNF-a released in the media, (b) IC50 on TNF-a production, and (c, d) cell surface maturation markers CD86 and CD83 relative expression. Non-treated cells (n.t.) are indicated.
Data correspond to at least 3 cell donors/independent assays. Bars represent means ± SEM.
Fig. 5. Delayed addition of compound 3 conserves inhibitory activity. DCs were left untreated (n.t.) or treated with LPS, either alone or with (a) compound 3 or (b) MGC 9, added at
the indicated times. TNF-a production was analyzed after 24 h. Data correspond to the mean (±SD) of n> 3 independent assays (each dot corresponds to an independent assay).
E. Schaeffer et al. / European Journal of Medicinal Chemistry 169 (2019) 111e120 115between the MGC and sp2-IGL LPS-signaling inhibitor families. We
have previously shown that MGC 9 at 100 mM elicited CD14 inter-
nalization from the cell surface and triggered the co-localization of
CD14 with the TLR-4, the two LPS co-receptors, thereby preventing
their availability to interact with the LPS at the cell membrane
leading to the inﬂammatory response [22]. To investigate whether
sp2-IGLs affected receptor co-localization, DCs were left untreated
or exposed for 30min to 100 mM of MGC 9 or 25 mM and 50 mM of
the D-gluco-conﬁgured sp2-IGLs 1, 2 and 3, followed by ﬂow
cytometry analysis of CD14 cell surface expression. As expected,
MGC 9 internalized CD14 from the cell surface, but none of the sp2-
IGLs reduced the CD14 concentration at the cell-surface (Fig. 6a). To
assess CD14dTLR-4 co-localization and the potential effect of var-
iations in the monosaccharide mimic conﬁgurational pattern, the
cells were next labeled with anti-CD14 and anti-TLR-4 antibodiesand treated with the more active D-gluco compounds, namely the
sulfoxide 1 and the sulfone 3, or the 3-epimers 6 and 8, and visu-
alized by confocal microscopy as described.18 In comparison to
untreated cells, MGC 9 provoked the co-localization of the two LPS
co-receptors. However, none of the sp2-IGLs, irrespective of the
glycone conﬁguration (1 and 3 for D-gluco, 6 for D-galacto and 8 for
D-manno) induced CD14dTLR-4 proximity (Fig. 6b). These data
show that sp2-IGLs have no impact on cellular LPS-receptor co-
localization and support the notion that their inhibitory mecha-
nism is different from that of MGCs.
2.6. sp2-Iminosugar glycolipid 3 inhibits acute inﬂammation in
mice
We next tested if sp2-IGL 3 can function as an anti-inﬂammatory
Fig. 6. Effect of sp2-IGLs on DCs membrane proteins. (a) Cell surface expression of CD14 analyzed by ﬂow cytometry, after 30min treatment with MGC 9 (100 mM) or compounds 1,
2, 3 (25 and 50 mM; light and deep blue dots, respectively). (b) Pearson coefﬁcient of colocalization of CD14 and TLR-4 in permeabilized DCs after 30min treatment with MGC 9
(100 mM) or compounds 1, 3, 6, 8 (50 mM). Each dot corresponds to a ﬁeld of 15e20 cells visualized by confocal microscopy. Data correspond to two independent assays. Dots above
the grey line (area noted as yes) indicate an increased tendency for colocalization. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
Web version of this article.)
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reasons, the response of the proinﬂammatory interleukin IL-6,
which reaches much higher concentrations in serum after LPS ad-
ministrations as compared with TNFa or other cytokines/chemo-
kines, was determined in this assay [32]. First, toxicity was assessed
by comparing the weight change of 2 female and 2 male C57BL/6J
mice after repeated intraperitoneal administration of sp2-IGL 3 or
control solvent for 4 successive days. There was no weight loss in
either female or male mice, demonstrating good tolerance of the
compound at this dose (Fig. 7a and b). Next, mice received intra-
peritoneally either a single dose of 50mg/kg of sp2-IGL 3 or solvent
control 1 h prior to a single peritoneal injection of 0.5mg/kg of LPS.
Two hours later, the mice were bled and serum prepared for IL-6Fig. 7. Compound 3 is active in a mouse model of acute LPS-induced inﬂammation. (a, b) T
treated with (a) control PBS/DMSO or (b) compound 3 (30mg/kg) administered i.p. on day 0
DMSO 2:1) or compound 3 (in PBS/DMSO; 50 mg/kg) administered i.p., 1 h before LPS (0.5 m
Bars are mean values ± SD of one typical experiment out of 2. * p  0.05.measures by ELISA. As expected [33], the proinﬂammatory cyto-
kine IL-6 rose to high levels in the blood in response to LPS. How-
ever, the administration of sp2-IGL 3 led to a signiﬁcant reduction in
IL-6 levels. These ﬁndings unequivocally show that sp2-IGL 3 re-
duces the inﬂammatory response to LPS stimulation in a mouse
model.3. Discussion
With the aim of exploring alternative therapeutic approaches
against inﬂammation, here we provide a proof-of-principle study,
which lays the foundation for novel strategies based on the use of
sp2-iminosugar glycolipids to modulate the intracellular eventshe weight curves of male and female C57BL/6J mice (relative to their weight on day 0)
, 1, 2, 3, shows the absence of toxic effect of 3. (c) Mice were treated with solvent (PBS/
g/kg) challenge. Histograms show the IL-6 production in serum 2 h after LPS injection.
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on the expression of LPS-elicited human dendritic cell maturation
markers upon treatment with the synthesized sp2-iminosugar
glycolipids evidenced the critical effect of the nature of the func-
tional group linking the glycone portion and the lipid chain in the
biological activity. The efﬁciency of the inﬂammatory response
inhibition is further modulated by the conﬁgurational pattern of
the sugar-like motif. Thus, sp2-IGLs with a hydroxylation proﬁle
analogous to that of a-D-glucose were more active than the corre-
sponding epimers with a-D-galactose or a-D-mannose conﬁgura-
tion. Nevertheless, the changes in the relative orientation of the
hydroxyl groups in the sugar-like portion did not affect drastically
their potential as anti-inﬂammatory agents. Sulfone 3 was identi-
ﬁed as the most active sp2-IGL in the series, exhibiting low toxicity
in vitro up to 50 mM and the capability to inhibit TNFa production in
a dose-dependent manner, with an IC50 of 20 mM. Time-course
addition experiments and determination of the CD14 and the
TLR-4 LPS-receptor localization revealed marked differences be-
tween the sp2-IGLs and a control glycolipid, MGC 9: whereas the
latter acts at the cell membrane level, preventing binding of LPS to
the CD14 and TLR-4 co-receptors, the sp2-IGLs do not; therefore,
they interfere with TLR-4 intracellular signaling. This is consistent
with the reported data suggesting that compound 3 interacts with
p38aMAPK in microglia [14]. The promise of small molecule kinase
inhibitors for patient beneﬁt in the context of autoimmune and
inﬂammatory processes is well recognized [34]. Finally, our results
provide evidence for the efﬁcacy of compound 3 in an in vivomodel
of LPS-mediated inﬂammation and incite further work on the po-
tential of sp2-IGLs in anti-inﬂammatory therapies.
4. Experimental
4.1. General methods
Reagents and solvents were purchased from commercial sour-
ces and used without further puriﬁcation. Optical rotations were
measured with a JASCO P-2000 polarimeter, using a sodium lamp
(l¼ 589 nm) at 22 C in 1 cm or 1 dm tubes. NMR experiments
were performed at 300 (75.5), 400 (100.6) and 500 (125.7) MHz for
1H (13C, respectively). 2-D COSY and HMQC experiments were
carried out to assist on signal assignment. In the FABMS spectra, the
primary beam consisted of Xe atoms with maximun energy of
8 keV. The samples were dissolved in m-nitrobenzyl alcohol or
thioglycerol as the matrices and the positive ions were separated
and accelerated over a potential of 7 keV. NaI was added as catio-
nizing agent. For ESI mass spectra, 0.1 pM sample concentrations
were used, the mobile phase consisting of 50% aq MeCN at
0.1mLmin1. Thin-layer chromatography was performed on pre-
coated TLC plates, silica gel 30F-245, with visualization by UV light
and by carring with 10% H2SO4 or 0.2% w/v cerium (IV) sulphate-5%
ammonium molybdate in 2 MH2SO4 or 0.1% ninhydrin in EtOH.
Column chromatography was performed on Chromagel (silice 60
AC.C 70e200 mm). Deacetylation reactions were carried out by us-
ing Zemplen procedure, e.i., addition of NaOMe (0.1 equiv/Ac mol)
in MeOH at room temperature, followed by neutralization with
solid CO2, evaporation of the solvent and puriﬁcation by column
chromatography. All compounds were puriﬁed to 95% purity as
determined by elemental microanalysis results obtained on a
CHNSTruSpect Micro elemental analyzer (Instituto de Inves-
tigaciones Quıímicas de Sevilla, Spain) fromvacuum-dried samples.
The analytical results for C, H, N, and S were within ±0.4 of the
theoretical values. Compounds 1e8 were examined for known
classes of assay interference compounds using the freely available
research tool for ligand discovery ZINC 15 (http://zinc15.docking.
org) [35].24 Starting materials 10 and 14 [36] and compounds 1e3were synthesized following reported procedures [12]. Mannoside
glycolipid conjugate (MGC) 9 was synthesized by the company
Roowin (Riom, France). The synthesis, physico-chemical properties
and cytotoxicity were previously reported [22e24].
4.2. Synthesis
4.2.1. (1R)-2,3,4-Tri-O-acetyl-1-dodecylthio-5N,6O-
oxomethylidenegalactonojirimycin (11)
To a stirred solution of (1R)-1,2,3,4-tetra-O-acetyl-5N,6O-oxo-
methylidenegalactonojirimycin (10, 0.29mmol) in anhydrous DCM
(4mL) at 0 C, BF3.OEt2 (134 mL, 1.09mmol) and dodecylthiol
(0.61mmol) were added under Ar atmosphere. The mixture was
stirred for 30min (TLC monitoring), diluted with DCM (50mL) and
washed with water (10mL), aq NaHCO3 (10mL) and brine (10mL),
dried (MgSO4) and concentrated under reduced pressure. Puriﬁ-
cation by column chromatography (1:3 EtOAc-cyclohexane) yiel-
ded 11 (118mg, 79%). Rf 0.68 (1:1 EtOAc-cyclohexane). [a]D þ161.7
(c 1.0 in DCM).1H NMR (500MHz, CDCl3): d 5.78 (d, 1 H, J1,2¼ 5.1 Hz,
H-1), 5.43 (t, 1 H, J3,4¼ J4,5¼1.6 Hz, H-4), 5.26e5.16 (m, 2 H, H-2, H-
3), 4.43e4.34 (m, 2 H, H-5, H-6a), 4.04 (dd, 1 H, J6a,6b¼ 13.5 Hz,
J5,6b¼ 10.0 Hz, H-6b), 2.57 (ddd, 1 H, 2JH,H¼ 12.7 Hz, 3JH,H¼ 8.3 Hz,
3JH,H¼ 6.0 Hz, SCH2), 2.43 (ddd, 1 H, SCH2), 2.17e2.00 (3 s, 9 H,
MeCO), 1.70e1.20 (m, 20 H, CH2), 0.87 (t, 3 H, 3JH,H¼ 7.0 Hz, CH3).13C
NMR (125.7MHz, CDCl3): d 170.4e169.8 (MeCO), 155.7 (CO), 68.9
(C-3), 68.4 (C-4), 67.2 (C-2), 62.8 (C-6), 58.1 (C-1), 50.4 (C-5),
32.0e22.8 (CH2), 30.4 (SCH2), 20.8e20.7 (MeCO), 14.2 (CH3). ESIMS:
m/z 538.5 [M þ Na]þ. HRFABMS Calcd for C25H41NO8SNa [M þ Na]þ
538.2451, found 538.2444.
4.2.2. (1R,SS)- and (1R,SR)-2,3,4-Tri-O-acetyl-1-dodecylsulﬁnyl-
5N,6O-oxomethylidenegalactonojirimycin (12 and 13)
To a solution of 11 (131mg, 0.23mmol) in DCM (6mL), mCPBA
(70%, 40mg, 0.23mmol) was added at 0 C. The reaction mixture
was stirred for 10min, diluted with DCM (50mL), washed with
aqueous NaHCO3 (10mL), brine (10mL), dried (MgSO4) and
concentrated under reduced pressure. The resulting crude was
puriﬁed by column chromatography (1:2 EtOAc-cyclohexane) to
afford the pure diastereomers 12 and 13.
Yield of 12: 44mg (35%). Rf 0.53 (3:2 EtOAc-cyclohexane).
[a]D þ68.4 (c 0.8 in DCM). 1H NMR (300MHz, CDCl3): d 5.72 (dd,
1 H, J2,3¼10.7 Hz, J3,4¼ 2.6 Hz, H-3), 5.49 (t, 1 H, J4,5¼ 2.6 Hz, H-4),
5.45 (dd, 1 H, J1,2¼ 7.5 Hz, H-2), 5.05 (d, 1 H, H-1), 4.96 (ddd, 1 H,
J5,6a¼ 9.2 Hz, J5,6b¼ 3.8 Hz, H-5), 4.50 (t, 1 H, J6a,6b¼ 9.2 Hz, H-6a),
4.07 (dd, 1 H, H-6b), 2.84 (ddd, 1 H, 2JH,H¼ 13.0 Hz, 3JH,H¼ 8.1 Hz,
3JH,H¼ 6.8 Hz, SOCH2), 2.65 (ddd, 1 H, SOCH2), 2.17e2.01 (2 s, 9 H,
MeCO), 1.78e1.20 (m, 20 H, CH2), 0.87 (t, 3 H, 3JH,H¼ 6.6 Hz, CH3).
13C NMR (75.5MHz, CDCl3): d 170.3e169.5 (MeCO), 157.3 (CO),
68.9e68.7 (C-3, C-4), 67.0e66.8 (C-1, C-2), 63.9 (C-6), 54.2 (C-5),
49.3 (SOCH2), 32.0e22.8 (CH2), 20.7 (MeCO), 14.2 (CH3). ESIMS:m/z
554.3 [M þ Na]þ. Anal. Calcd for C25H41NO9S: C, 56.48; H, 7.77; N,
2.63; S, 6.03. Found: C, 56.63; H, 7.90; N, 2.44; S, 5.79.
Yield of 13: 39mg (32%). Rf 0.47 (3:2 EtOAc-cyclohexane).
[a]D þ75.4 (c 1.0 in DCM). 1H NMR (300MHz, CDCl3): d 5.65 (dd,
1 H, J2,3¼10.8 Hz, J3,4¼ 2.6 Hz, H-3), 5.58e5.48 (m, 2 H, H-2, H-4),
5.23 (d, 1 H, J1,2¼ 6.2 Hz, H-1), 4.42 (t, 1 H, J5,6a¼ J6a,6b¼ 9.0 Hz, H-
6a), 4.29 (ddd, 1 H, J5,6b¼ 4.1 Hz, J4,5¼1.6 Hz, H-5), 4.07 (dd, 1 H, H-
6b), 2.98 (ddd, 1 H, 2JH,H¼ 13.0 Hz, 3JH,H¼ 9.3 Hz, 3JH,H¼ 5.3 Hz,
SOCH2), 2.71 (m, 1 H, SOCH2), 2.18e2.02 (3 s, 9 H, MeCO), 1.90e1.18
(m, 20 H, CH2), 0.87 (t, 3 H, 3JH,H¼ 6.6 Hz, CH3). 13C NMR (75.5MHz,
CDCl3): d 170.3e169.5 (MeCO), 157.3 (CO), 68.9 (C-3), 68.7 (C-4),
67.0 (C-1), 66.8 (C-2), 63.9 (C-6), 52.2 (C-5), 49.3 (SOCH2),
32.0e22.7 (CH2), 20.7 (MeCO), 14.2 (CH3). ESIMS: m/z 554.3 [M þ
Na]þ. Anal. Calcd for C25H41NO9S: C, 56.48; H, 7.77; N, 2.63; S, 6.03.
Found: C, 56.55; H, 7.63; N, 2.31; S, 5.67.
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oxomethylidenegalactonojirimycin (4)
Compound 4 was obtained from 12 (30mg, 0.06mmol) by
conventional O-deacetylation (see General Methods) and puriﬁca-
tion by column chromatography (4:1 EtOAc-cyclohexane /
EtOAc). Yield: 24mg (98%). Rf 0.09 (EtOAc). [a]D þ64.1 (c 1.0 in
MeOH). 1H NMR (300MHz, CD3OD): d 4.51 (t, 1 H,
J6a,6b¼ J5,6a¼ 8.6 Hz, H-6a), 4.42 (dd, 1 H, J5,6b¼ 5.4 Hz, H-6b), 4.35
(ddd, 1 H, J4,5¼ 2.0 Hz, H-5), 4.29 (dd, 1 H, J2,3¼ 9.9 Hz, J1,2¼ 6.8 Hz,
H-2), 3.99 (dd, 1 H, J3,4¼ 2.5 Hz, H-3), 3.88 (t, 1 H, H-4), 3.00e2.82
(m, 2 H, SOCH2), 1.84e1.73 (m, 2 H, SOCH2CH2), 1.58e1.21 (m, 18 H,
CH2), 0.90 (t, 3 H, 3JH,H¼ 6.5 Hz, CH3). 13C NMR (75.5MHz, CD3OD):
d 160.2 (CO), 72.8e72.4 (C-1, C-3), 70.1 (C-4), 67.7 (C-2), 65.5 (C-6),
57.3 (C-5), 51.9 (SOCH2), 33.0e23.7 (CH2), 14.4 (CH3). ESIMS: m/z
428.2 [M þ Na]þ. Anal. Calcd for C19H35NO6S: C, 56.27; H, 8.70; N,
3.45; S, 7.91. Found: C, 56.16; H, 8.65; N, 3.13; S, 7.60.
4.2.4. (1R,SR)-1-Dodecylsulﬁnyl-5N,6O-
oxomethylidenegalactonojirimycin (5)
Compound 5 was obtained from 13 (21mg, 0.04mmol) by
conventional O-deacetylation (see General Methods) and ﬁnal pu-
riﬁcation by column chromatography (4:1 EtOAc-cyclohexane /
EtOAc). Yield: 15mg (96%). Rf 0.09 (EtOAc). [a]D þ65.0 (c 1.0 in
MeOH). 1H NMR (300MHz, CD3OD): d 4.96 (d, 1 H, J1,2¼ 6.5 Hz, H-
1), 4.50e4.40 (m, 2 H, H-6a, H-6b), 4.37 (dd, 1 H, J2,3¼10.0 Hz, H-2),
4.16 (ddd, 1 H, J5,6a¼ 8.7 Hz, J5,6b¼ 5.2 Hz, J4,5¼ 2.0 Hz, H-5), 4.05
(dd, 1 H, J3,4¼ 2.5 Hz, H-3), 3.90 (t, 1 H, H-4), 3.12 (ddd, 1 H,
2JH,H¼ 13.0 Hz, 3JH,H¼ 8.7 Hz, 3JH,H¼ 5.8 Hz, SOCH2), 2.98 (ddd, 1H,
SOCH2), 1.87e1.70 (m, 2 H, SO2CH2CH2), 1.60e1.21 (m, 18 H, CH2),
0.90 (t, 3 H, 3JH,H¼ 6.8 Hz, CH3). 13C NMR (75.5MHz, CD3OD):
d 159.2 (CO), 73.1e72.3 (C-1, C-3), 70.0 (C-4), 69.5 (C-2), 65.3 (C-6),
56.5 (C-5), 50.8 (SOCH2), 33.1e23.7 (CH2), 14.4 (CH3). ESIMS: m/z
428.2 [M þ Na]þ. Anal. Calcd for C19H35NO6S: C, 56.27; H, 8.70; N,
3.45; S, 7.91. Found: C, 56.30; H, 8.90; N, 3.17; S, 7.75.
4.2.5. (1R)-1-Dodecylsulfonyl-5N,6O-
oxomethylidenegalactonojirimycin (6)
To a solution of 11 (51mg, 0.09mmol) in DCM (3mL), mCPBA
(70%, 31mg, 0.18mmol) was added at 0 C. The reaction mixture
was stirred for 20min, diluted with DCM (50mL), washed with
aqueous NaHCO3 (10mL), brine (10mL), dried (MgSO4), concen-
trated under reduced pressure. Further puriﬁcation by column
chromatography (4:1 EtOAc-cyclohexane / EtOAc) and conven-
tional O-deacetylation (see General Methods) afforded 6. Yield:
18mg (47% global yield). Rf 0.20 (EtOAc). [a]Dþ23.2 (c 1.0 inMeOH).
1H NMR (300MHz, CD3OD): d 5.16 (d, 1 H, J1,2¼ 6.0 Hz, H-1), 4.50 (t,
1 H, J6a,6b¼ J5,6a¼ 8.5 Hz, H-6a), 4.42 (dd, 1 H, J5,6b¼ 5.2 Hz, H-6b),
4.31 (ddd, 1 H, J4,5¼1.7 Hz, H-5), 4.28e4.24 (m, 2 H, H-2, H-3), 3.88
(t, 1 H, J3,4¼1.7 Hz, H-4), 3.39e3.34 (m, 2 H, SO2CH2), 1.84 (m, 2 H,
3JH,H¼ 7.2 Hz, SO2CH2CH2), 1.48e1.29 (m, 18 H, CH2), 0.90 (t, 3 H,
3JH,H¼ 6.7 Hz, CH3). 13C NMR (75.5MHz, CD3OD): d 159.2 (CO), 72.3
(C-1), 70.7 (C-2), 70.2 (C-4), 67.8 (C-3), 65.4 (C-6), 56.3 (C-5,
CH2SO2), 33.0e22.5 (CH2), 14.4 (CH3). ESIMS: m/z 444.2 [M þ Na]þ.
Anal. Calcd for C19H35NO7S: C, 54.14; H, 8.37; N, 3.32; S, 7.61. Found:
C, 53.90; H, 8.18; N, 3.11; S, 7.28.
4.2.6. (1R)-2,3,4-Tri-O-acetyl-1-dodecylthio-5N,6O-
oxomethylidenemannonojirimycin (15)
To a stirred solution of (1R)-1,2,3,4-tetra-O-acetyl-5N,6O-oxo-
methylidenemannojirimycin (14, 0.29mmol) in anhydrous DCM
(4mL) at 0 C, BF3.OEt2 (134 mL, 1.09mmol) and dodecylthiol
(0.61mmol) were added under Ar atmosphere. The mixture was
stirred for 30min (TLC monitoring), diluted with DCM (50mL) and
washed with water (10mL), aq NaHCO3 (10mL) and brine (10mL),
dried (MgSO4) concentrated under reduced pressure and subjectedto column chromatography (1:4/1:2 EtOAc-cyclohexane) to give
15. Yield: 101mg (68%). Rf 0.72 (1:1 EtOAc-cyclohexane). [a]Dþ18.2
(c 1.0 in DCM). 1H NMR (300MHz, CDCl3): d 5.33e5.28 (m, 2 H, H-2,
H-3), 5.22 (t, 1 H, J3,4¼ J4,5¼ 9.9 Hz, H-4), 5.15 (d, 1 H, J1,2¼ 2.0 Hz,
H-1), 4.41 (dd, 1 H, J6a,6b¼ 9.1 Hz, J5,6a¼ 8.2 Hz, H-6a), 4.32 (dd, 1 H,
J5,6b¼ 5.1 Hz, H-6b), 4.08 (ddd, 1 H, H-5), 2.73e2.51 (m, 2 H, CH2S),
2.10e1.99 (3 s, 9 H, MeCO), 1.67e1.51 (m, 2 H, CH2CH2S), 1.41e1.17
(m, 18 H, CH2), 0.86 (t, 3 H, 3JH,H¼ 6.6 Hz, CH3).13C NMR (75.5MHz,
CDCl3): d 170.3e169.6 (MeCO), 156.3 (CO), 70.8, 69.1 (C-2, C-3), 69.5
(C-4), 66.1 (C-6), 58.3 (C-1), 52.8 (C-5), 31.9e28.7 (CH2), 20.8e20.6
(MeCO), 14.2 (CH3). ESIMS: m/z 538.3 [M þ Na]þ. Anal. Calcd for
C25H41NO8S: C, 58.23; H, 8.01; N, 2.72; S, 6.22. Found: C, 58.32; H,
8.20; N, 2.60; S, 6.04.
4.2.7. (1R,SS)-2,3,4-Tri-O-acetyl-1-dodecylsulﬁnyl-5N,6O-
oxomethylidenemannonojirimycin (16)
To a solution of 15 (131mg, 0.23mmol) in DCM (6mL), mCPBA
(70%, 40mg, 0.23mmol) was added at 0 C. The reaction mixture
was stirred for 10min, diluted with DCM (50mL), washed with
aqueous NaHCO3 (10mL), brine (10mL), dried (MgSO4) and
concentrated under reduced pressure. The resulting crude was
puriﬁed by column chromatography (Et2O) to give 16. Yield: 48mg
(39%). Rf 0.59 (Et2O). [a]D - 4.1 (c 1.0 in DCM). 1H NMR (300MHz,
CDCl3): d 5.73 (t, 1 H, J1,2¼ J2,3¼ 2.5 Hz, H-2), 5.61 (dd, 1 H,
J3,4¼ 9.0 Hz, H-3), 5.27 (t, 1 H, J4,5¼ 9.0 Hz, H-4), 4.62 (d, 1 H, H-1),
4.60e4.50 (m, 1 H, H-5), 4.52 (t, 1 H, J6a,6b¼ J5,6a¼ 8.3 Hz, H-6a),
4.38 (dd,1 H, J5,6b¼ 3.7 Hz, H-6b), 2.95 (m,1 H, SOCH2), 2.79 (m,1 H,
SOCH2), 2.16e2.01 (3 s, 9 H, MeCO),1.79e1.18 (m, 20 H, CH2), 0.87 (t,
3 H, 3JH,H¼ 6.9 Hz, CH3). 13C NMR (75.5MHz, CDCl3): d 170.3e169.4
(MeCO), 157.7 (CO), 69.6 (C-2), 69.0 (C-3), 68.8 (C-4), 68.4 (C-1), 66.9
(C-6), 55.8 (C-5), 50.8 (SOCH2), 31.9e22.4 (CH2), 20.7e20.6 (MeCO),
14.1 (CH3). ESIMS:m/z 554.5 [MþNa]þ. Anal. Calcd for C25H41NO9S:
C, 56.48; H, 7.77; N, 2.63; S, 6.03. Found: C, 56.13; H, 7.44; N, 2.29; S,
5.76.
4.2.8. (1R,SS)-1-Dodecylsulﬁnyl-5N,6O-
oxomethylidenemannonojirimycin (7)
Compound 7 was obtained from 16 (20mg, 0.04mmol) by
conventional O-deacetylation. Column chromatography (5:1
EtOAc-MeOH). Yield: 14mg (86%). Rf 0.52 (5:1 EtOAc-MeOH).
[a]D þ23.8 (c 0.6 in MeOH). 1H NMR (300MHz, CD3OD): d 4.67 (d,
1 H, J1,2¼ 2.0 Hz, H-1), 4.63 (t, 1 H, J6a,6b¼ J5,6a¼ 8.7 Hz, H-6a), 4.38
(t, 1 H, J2,3¼ 2.0 Hz, H-2), 4.34 (dd, 1 H, J5,6b¼ 4.9 Hz, H-6b), 4.11
(ddd, 1 H, J4,5¼ 9.3 Hz, H-5), 3.90 (dd, 1 H, J2,3¼ 2.0 Hz, J3,4¼ 9.3 Hz,
H-3), 3.75 (t, 1 H, H-4), 2.98e2.81 (m, 2 H, SOCH2), 1.82e1.71 (m,
2 H, SOCH2CH2), 1.52e1.24 (m, 18 H, CH2), 0.90 (t, 3 H, 3JH,H¼ 6.7 Hz,
CH3). 13C NMR (75.5MHz, CD3OD): d 160.5 (CO), 73.6e73.0 (C-1, C-
3), 71.9e71.2 (C-2, C-4), 68.7 (C-6), 58.9 (C-5), 51.1 (SOCH2),
33.1e23.6 (CH2), 14.5 (CH3). ESIMS:m/z 428.3 [Mþ Na]þ. HRFABMS
Calcd for C19H35NO6SNa [M þ Na]þ 428.2077, found 428.2081.
4.2.9. (1R)-2,3,4-Tri-O-acetyl-1-dodecylsulfonyl-5N,6O-
oxomethylidenemannojirimycin (17)
To a solution of 15 (51mg, 0.09mmol) in DCM (3mL), mCPBA
(70%, 31mg, 0.18mmol) was added at 0 C. The reaction mixture
was stirred for 20min, diluted with DCM (50mL), washed with
aqueous NaHCO3 (10mL), brine (10mL), dried (MgSO4) and
concentrated under reduced pressure. Final puriﬁcation by column
chromatography (1:3 EtOAc-cyclohexane) afforded 17. Yield: 33mg
(71%). Rf 0.66 (1:1 EtOAc-cyclohexane). [a]D 6.5 (c 1.0 in DCM). 1H
NMR (300MHz, CDCl3): d 5.93 (t, 1 H, J1,2¼ J2,3¼ 2.6 Hz, H-2), 5.54
(dd, 1 H, J3,4¼ 9.0 Hz, H-3), 5.21 (t, 1 H, J4,5¼ 9.0 Hz, H-4), 5.06 (d,
1 H, H-1), 4.56e4.49 (m, 1 H, H-6a), 4.43e4.37 (m, 2 H, H-5, H-6b),
3.05 (m, 2 H, SO2CH2), 2.13e2.02 (3 s, 9 H, MeCO),1.95e1.78 (m, 2 H,
SO2CH2CH2), 1.46e1.19 (m, 18 H, CH2), 0.87 (t, 3 H, 3JH,H¼ 6.7 Hz,
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(CO), 69.4 (C-1), 69.0 (C-4), 68.9 (C-3), 67.2 (C-6), 65.0 (C-2), 54.1 (C-
5), 52.2 (CH2SO2), 32.0e21.7 (CH2), 20.8e20.6 (MeCO), 14.2 (CH3).
ESIMS:m/z 570.4 [M þ Na]þ. Anal. Calcd for C25H41NO10S: C, 54.83;
H, 7.55; N, 2.56; S, 5.85. Found: C, 55.01; H, 7.69; N, 2.29; S, 5.62.4.2.10. (1R)-1-Dodecylsulfonyl-5N,6O-
oxomethylidenemannonojirimycin (8)
Compound 8was obtained by conventional O-deacetylation (see
General Methods) of 17. Column chromatography (4:1 EtOAc-
cyclohexane / EtOAc). Yield: 12mg (64%). Rf 0.20 (EtOAc).
[a]D þ23.2 (c 1.0 in MeOH). 1H NMR (300MHz, CD3OD): d 5.03 (d,
1 H, J1,2¼1.6 Hz, H-1), 4.65e4.59 (m, 2 H, H-2, H-6a), 4.36 (dd, 1 H,
J6a,6b¼ 9.0 Hz, J5,6b¼ 5.0 Hz, H-6b), 4.08 (td, 1 H, J4,5¼ J5,6a¼ 9.0 Hz,
H-5), 3.86 (dd, 1 H, J3,4¼ 9.5 Hz, J2,3¼ 3.1 Hz, H-3), 3.73 (t, 1 H, H-4),
3.25e3.06 (m, 2 H, SO2CH2), 1.89e1.73 (m, 2 H, SO2CH2CH2),
1.47e1.26 (m, 18 H, CH2), 0.89 (t, 3 H, 3JH,H¼ 6.7 Hz, CH3). 13C NMR
(75.5MHz, CD3OD): d 159.5 (CO), 74.0 (C-1), 73.0 (C-3), 70.7 (C-4),
68.6 (C-6), 66.9 (C-2), 57.0 (C-5), 52.0 (CH2SO2), 32.0e22.7 (CH2),
14.4 (CH3). ESIMS: m/z 444.3 [M þ Na]þ. Anal. Calcd for
C19H35NO7S: C, 54.14; H, 8.37; N, 3.32; S, 7.61. Found: C, 53.88; H,
8.12; N, 3.04; S, 7.32.4.3. Cell culture
Human primary cells were cultured at 37 C and 5% CO2 in RPMI
1640 supplemented with gentamycin and 10% (v/v) heat-
inactivated fetal calf serum (complete medium). Human mono-
cytes were puriﬁed from buffy coats by successive Ficoll and Percoll
gradients. Monocyte-derived DCs were differentiated from mono-
cytes by 5 days of culture with GM-CSF (50 ngml1; ImmunoTools)
and IL-4 (10 ngml1; ImmunoTools), as described.19 Proper differ-
entiation was characterized by low CD14 and high CD1a and DC-
SIGN expression levels.4.4. Flow cytometry
The cell phenotype was analyzed using the following antibodies
from BD Bioscience: HLA-DR-FITC (Tü39 or L243), DC-SIGN/CD209-
PerCP-Cy5.5 (DCN46), CD1a-APC (HI149), CD86-FITC (FUN-1),
CD83-APC (HB15e), and CD14-PE (MEM-15, ImmunoTools). Data
were acquired on a FACSCalibur (Becton-Dickinson) or Gallios
(Beckman-Coulter) after exclusion of dead cells by Sytox Red
(Molecular Probes, Invitrogen) or 7-AAD (BD-Pharmingen) DNA
intercalating dyes. Data were analyzed using the Cell Quest Pro
software (BD Bioscience) or FlowJo (Treestar).4.5. Cell activation
DCs (105 cells/well) were cultured in complete medium (200 mL)
and incubated in the presence of Ultra pure E. coli K12 lipopoly-
saccharide (LPS; 100 ngmL1). Compounds were usually added at
the same time as LPS, or, where indicated, 2, 4 or 6 h after LPS
addition.4.6. Enzyme-linked ImmunoabSorbent Assay (ELISA)
After 24 h of stimulation with LPS, cell supernatants were
collected and stored at 20 C. Levels of TNF-a released in the
media, or in the case of in vivo assays, levels of IL-6 in the mouse
sera, were measured by ELISA with the corresponding BD OptEIA
Set (BD-Pharmingen).4.7. Effect on cell surface proteins
DCs (105 cells) in complete medium (200 mL) were plated in a
96-well plate. They were left untreated or treated with sp2-IGLs (25
and 50 mM) or conjugate MGC 9 (100 mM) for 30min at 37 C. They
were washed, kept on ice, labeled with anti-CD14-PE, and analyzed
by ﬂow cytometry.
4.8. Co-localization analysis of CD14 and TLR-4 by confocal
microscopy
Assays were performed according to the previously described
procedure [22]. Brieﬂy, DCs (105 cells per chamber) were cultured
on poly-L-Lysine-coated, 8-chambers slides (Lab-Tek, Nunc) in
complete medium (300 mL). Cells were left untreated or treated
with sp2-IGLs (50 mM) or MGC 9 (100 mM) for 30min. Cells were
washed, ﬁxed, permeabilized and labeled with anti-TLR-4 poly-
clonal goat antibody (R&D Systems AF1478, 5 mgmL1) followed by
AF488-donkey anti-goat (Molecular Probes, Invitrogen), and anti-
CD14-APC (ImmunoTools). DAPI was used as nuclear counter-
staining. Slides were mounted using Fluoromount (Dako). Images
were acquired on a Zeiss LSM 780 confocal microscope with GaAsP
detector and Zen acquisition software. Images were processed us-
ing the ImageJ software.
4.9. In vivo assays in C57BL/6J mice
All animals received humane care in compliance with the
guidelines formulated by the French Ministry of Agriculture and of
Higher Education and Research, and all procedures were reviewed
by the Regional Ethical Committee for Animal Experimentation of
the University of Strasbourg. sp2-IGL 3 was prepared in sterile
solvent (7.25mgmL1) by solubilization in DMSO (10.5mg in 1mL)
followed by addition of H2O (0.5mL) and PBS x10 (150 mL). LPS
(0.5mg/kg; strain O111.B4; Sigma-Aldrich) was prepared in sterile
PBS. To evaluate the in vivo toxicity of the compound, 8-week old
male and female mice received intraperitoneal (i.p.) administra-
tions of 200 ml of sp2-IGL 3 (30mg/kg) or of control DMSO/PBS on
day 0, 1, 2, 3. Evaluation of their well-being and weight were per-
formed every day up to day 12. To assess the compounds for their
capacity to block LPS-induced IL-6 production, C57BL/6J male 8-
week old mice received a single intraperitoneal (i.p.) administra-
tion of sp2-IGL 3 (50mg/kg) 1 h before LPS (0.5mg/kg) challenge.
Control animals received equivalent volumes of solvent (PBS or
PBS/DMSO 2:1) (200 mL) by the intraperitoneal route. Blood
(150 mL) was taken 2 h after LPS injection. Serumwas prepared and
IL-6 measured by ELISA (see above).
Statistical Analysis. Statistical analysis was performed using
paired Student's t-test. Data were considered signiﬁcantly different
when p was less than 0.05.
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